#Cancer Drug Innovation Surges As Cost Growth Moderates - FiercePharmaMarketing
▻http://www.fiercepharmamarketing.com/press-releases/ims-health-study-cancer-drug-innovation-surges-cost-growth-mo
In the U.S. market, which contributes 41 percent of total oncology drug sales, changes in the structure of healthcare delivery are impacting cancer treatment site of care, reimbursement and patient out-of-pocket costs. Physician practices are becoming larger, and healthcare organizations that care for underserved populations and are covered by the 340B Drug Discount Program have expanded their oncology presence, as have Accountable Care Organizations. This is resulting in a shift in patient care from physician offices to hospital outpatient facilities. (...) These higher costs are also associated with higher patient out-of-pocket costs depending on insurance plans and benefit designs, and can trigger reduced levels of therapeutic persistence by patients and higher overall cost of care.
via @jamielove